Determinant factors for first-line treatment choice and effectiveness in pediatric eosinophilic esophagitis: an analysis of the EUREOS EoE CONNECT registry.

This study compared short-term effectiveness of proton pump inhibitors (PPI), swallowed topical corticosteroids (STC), and dietary therapies in reversing clinical and histological features in pediatric patients with eosinophilic esophagitits (EoE). Determinants for treatment choice and PPI therapy effectiveness were also assessed.  A cross-sectional study analysis of patients under 18 years old recruited onto the multicenter EoE CONNECT registry was performed. Clinico-histological response was defined as symptomatic improvement plus a peak eosinophil count below 15 per high-power field after treatment. Effectiveness of first-line options used in monotherapy was compared. Overall, 393 patients (64% adolescents) receiving PPI, STC, or dietary monotherapy to induce EoE remission were identified. PPI was the preferred option (71.5%), despite STC providing the highest clinico-histological response rates (66%) compared to PPI (44%) and diet (42%). Logistic regression identified fibrotic features and recruitment at Italian sites independently associated to first-line STC treatment; age under 12 associated to dietary therapy over other options. Analysis of 262 patients in whom PPI effectiveness was evaluated after median (IQR) 96 (70-145) days showed that this effectiveness was significantly associated with management at pediatric facilities and use of high PPI doses. Among PPI responders, decrease in rings and structures in endoscopy from baseline was documented, with EREFS fibrotic subscore for rings also decreasing among responders (0.27 ± 0.63 vs. 0.05 ± 0.22, p < 0.001). Conclusion: Initial therapy choice for EoE depends on endoscopic phenotype, patient's age, and patients' origin. High PPI doses and treatment in pediatric facilities significantly determined effectiveness, and reversed fibrotic endoscopic features among responders. What is Known: • Proton pump inhibitors are widely used to induce and maintain remission in EoE in real practice, despite other first-line alternative therapies possibly providing higher effectiveness. What is New: • Proton pump inhibitors represent up to two-thirds of first-line monotherapies used to induce EoE remission in pediatric and adolescent patients with EoE. The choice of STC as first-line treatment for EoE was significantly associated with fibrotic features at baseline endoscopy and recruitment in Italian centers; age less than 12 years was associated with dietary therapy. • PPI effectiveness was found to be determined by use of high doses, attendance at pediatric facilities, presenting inflammatory instead of fibrotic or mixed phenotypes, and younger age. Among responders, PPI therapy reversed both inflammatory and fibrotic features of EoE after short-term treatment.

Differences between childhood- and adulthood-onset eosinophilic esophagitis: An analysis from the EoE connect registry.

BACKGROUND: Direct comparisons of childhood- and adulthood-onset eosinophilic esophagitis (EoE) are scarce. AIM: To compare disease characteristics, endoscopic and histological features, allergic concomitances and therapeutic choices across ages. METHODS: Cross-sectional analysis of the EoE CONNECT registry. RESULTS: The adulthood-onset cohort (those diagnosed at ≥18y) comprised 1044 patients and the childhood-onset cohort (patients diagnosed at <18 y), 254. Vomiting, nausea, chest and abdominal pain, weight loss, slow eating and food aversion were significantly more frequent in children; dysphagia, food bolus impaction and heartburn predominated in adults. A family history of EoE was present in 16% of pediatric and 8.2% of adult patients (p<0.001). Concomitant atopic diseases did not vary across ages. Median±IQR diagnostic delay (years) from symptom onset was higher in adults (2.7 ± 6.1) than in children (1 ± 2.1; p<0.001). Esophageal strictures and rings predominated in adults (p<0.001), who underwent esophageal dilation more commonly (p = 0.011). Inflammatory EoE phenotypes were more common in children (p = 0.001), who also presented higher eosinophil counts in biopsies (p = 0.015) and EREFS scores (p = 0.017). Despite PPI predominating as initial therapy in all cohorts, dietary therapy and swallowed topical corticosteroids were more frequently prescribed in children (p<0.001). CONCLUSIONS: Childhood-onset EoE has differential characteristics compared with adulthood-onset, but similar response to treatment.

Successful Integration of Clinical Pharmacists in an OPAT Program: A Real-Life Multidisciplinary Circuit.

Outpatient parenteral antimicrobial therapy (OPAT) programs encompass a range of healthcare processes aiming to treat infections at home, with the preferential use of the intravenous route. Although several barriers arise during the implementation of OPAT circuits, recent cumulative data have supported the effectiveness of these programs, demonstrating their application in a safe and cost-effective manner. Given that OPAT is evolving towards treating patients with higher complexity, a multidisciplinary team including physicians, pharmacists, and nursing staff should lead the program. The professionals involved require previous experience in infectious diseases treatment as well as in outpatient healthcare and self-administration. As we describe here, clinical pharmacists exert a key role in OPAT multidisciplinary teams. Their intervention is essential to optimize antimicrobial prescriptions through their participation in stewardship programs as well as to closely follow patients from a pharmacotherapeutic perspective. Moreover, pharmacists provide specialized counseling on antimicrobial treatment technical compounding. In fact, OPAT elaboration in sterile environments and pharmacy department clean rooms increases OPAT stability and safety, enhancing the quality of the program. In summary, building multidisciplinary teams with the involvement of clinical pharmacists improves the management of home-treated infections, promoting a safe self-administration and increasing OPAT patients' quality of life.

Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT Registry.

BACKGROUND: Poor adherence to clinical practice guidelines for eosinophilic esophagitis (EoE) has been described and the diagnostic delay of the disease continues to be unacceptable in many settings. OBJECTIVE: To analyze the impact of improved knowledge provided by the successive international clinical practice guidelines on reducing diagnostic delay and improving the diagnostic process for European patients with EoE. METHODS: Cross-sectional analysis of the EoE CONNECT registry based on clinical practice. Time periods defined by the publication dates of four major sets of guidelines over 10 years were considered. Patients were grouped per time period according to date of symptom onset. RESULTS: Data from 1,132 patients was analyzed and median (IQR) diagnostic delay in the whole series was 2.1 (0.7-6.2) years. This gradually decreased over time with subsequent release of new guidelines (p < 0.001), from 12.7 years up to 2007 to 0.7 years after 2017. The proportion of patients with stricturing of mixed phenotypes at the point of EoE diagnosis also decreased over time (41.3% vs. 16%; p < 0.001), as did EREFS scores. The fibrotic sub-score decreased from a median (IQR) of 2 (1-2) to 0 (0-1) when patients whose symptoms started up to 2007 and after 2017 were compared (p < 0.001). In parallel, symptoms measured with the Dysphagia Symptoms Score reduced significantly when patients with symptoms starting before 2007 and after 2012 were compared. A reduction in the number of endoscopies patients underwent before the one that achieved an EoE diagnosis, and the use of allergy testing as part of the diagnostic workout of EoE, also reduced significantly over time (p = 0.010 and p < 0.001, respectively). CONCLUSION: The diagnostic work-up of EoE patients improved substantially over time at the European sites contributing to EoE CONNECT, with a dramatic reduction in diagnostic delay.

Perinatal outcome of macrosomic infants born to diabetic versus non-diabetic mothers. / Resultados perinatales entre macrosomas hijos de madre diabética y macrosomas hijos de madre no diabética.

OBJECTIVE: To assess the incidence and perinatal complications of macrosomic infants born to diabetic and non-diabetic mothers. PATIENTS AND METHODS: A six-year retrospective study of newborns at our hospital. A total of 996 macrosomic newborns were found. Maternal characteristics, mode of delivery, and perinatal outcomes were studied. RESULTS: Of 18005 newborns, 996 were macrosomic infants (5.53%). Of these, 103 (10.3%) were born to diabetic mothers. Diabetic mothers had higher parity (1.89 vs. 1.35; P<0.000), cesarean section rate (52.4 vs. 31.1%; P<0.05), and resuscitation rate (5.8 vs. 1.8%; P<0.006; RR: 2.9; 95% CI: 1.42-5.9), and greater need for hospitalization (19.4 vs. 9.6%; p<0.002; RR: 2; 95% CI: 1.3-3.2) and intensive care (5.8 vs. 0.7%; P<0.000; RR: 5.3; 95% CI: 2.8-10) mostly for hypoglycemia (7.8 vs. 1%; P<0.000; RR: 5; 95% CI: 2.8-8.3), jaundice (8.7 vs. 2.1%; P<0.000; RR: 3.1; 95% CI: 1.9-5.9), respiratory distress (4.9 vs. 1.3%; P<0.009; RR: 2.9; 95% CI: 1.4-6.7), and asphyxia (2.9 vs. 0.4%; P<0.005; RR: 4.3; 95% CI: 1.8-11.1). No differences were found in birth trauma. CONCLUSIONS: Macrosomic infants born to diabetic mothers have an increased risk of hospital admission in the neonatal period for hypoglycemia, jaundice, respiratory distress, and asphyxia, and a greater need of intensive care. Obstetric trauma rates were similar in both groups.

Resultados perinatales entre macrosomas hijos de madre diabética y macrosomas hijos de madre no diabética / Perinatal outcome of macrosomic infants born to diabetic versus non-diabetic mothers

Antecedentes y objetivo: Determinar la incidencia y las complicaciones perinatales de los recién nacidos macrosomas hijos de madre diabética y macrosomas hijos de madre no diabética. Pacientes y método: Estudio retrospectivo de 6 años de los macrosomas nacidos en nuestro hospital. Se encontraron 996 macrosomas. Se estudiaron características maternas, tipo de parto y resultados perinatales. Resultados: De 18.005 neonatos, 996 fueron macrosomas (5,53%), siendo 103 hijos de madre diabética (10,3%). La madres diabéticas tenían mayor paridad (1,89 vs. 1,35; p<0,000), porcentaje de cesáreas (52,4 vs. 31,1%; p<0,05), porcentaje de reanimación (5,8 vs. 1,8%; p<0,006; RR: 2,9; IC 95%: 1,42-5,9), mayor necesidad de ingreso hospitalario (19,4 vs. 9,6%; p<0,002; RR: 2; IC 95%: 1,3-3,2) y en cuidados intensivos (5,8 vs. 0,7%; p<0,000; RR: 5,3; IC 95%: 2,8-10); mayor cantidad de ingresos por hipoglucemia (7,8 vs. 1%; p<0,000; RR: 5; IC 95%: 2,8-8,3), ictericia (8,7 vs. 2,1%; p<0,000; RR: 3,1; IC 95%: 1,9-5,9), distrés respiratorio (4,9 vs. 1,3%; p<0,009; RR: 2,9; IC 95%: 1,4-6,7) y asfixia (2,9 vs. 0,4%; p<0,005; RR: 4,3; IC 95%: 1,8-11,1). No existieron diferencias en cuanto a traumatismos obstétricos. Conclusiones: Los recién nacidos macrosomas hijos de madre diabética tienen mayor riesgo de ingreso en el periodo neonatal, incluidos los ingresos por hipoglucemia, ictericia, asfixia, distrés respiratorio y mayor necesidad de cuidados intensivos. Los traumatismos obstétricos son similares (AU)

Objective: To assess the incidence and perinatal complications of macrosomic infants born to diabetic and non-diabetic mothers. Patients and methods: A six-year retrospective study of newborns at our hospital. A total of 996 macrosomic newborns were found. Maternal characteristics, mode of delivery, and perinatal outcomes were studied. Results: Of 18005 newborns, 996 were macrosomic infants (5.53%). Of these, 103 (10.3%) were born to diabetic mothers. Diabetic mothers had higher parity (1.89 vs. 1.35; P<0.000), cesarean section rate (52.4 vs. 31.1%; P<0.05), and resuscitation rate (5.8 vs. 1.8%; P<0.006; RR: 2.9; 95% CI: 1.42-5.9), and greater need for hospitalization (19.4 vs. 9.6%; p<0.002; RR: 2; 95% CI: 1.3-3.2) and intensive care (5.8 vs. 0.7%; P<0.000; RR: 5.3; 95% CI: 2.8-10) mostly for hypoglycemia (7.8 vs. 1%; P<0.000; RR: 5; 95% CI: 2.8-8.3), jaundice (8.7 vs. 2.1%; P<0.000; RR: 3.1; 95% CI: 1.9-5.9), respiratory distress (4.9 vs. 1.3%; P<0.009; RR: 2.9; 95% CI: 1.4-6.7), and asphyxia (2.9 vs. 0.4%; P<0.005; RR: 4.3; 95% CI: 1.8-11.1). No differences were found in birth trauma. Conclusions: Macrosomic infants born to diabetic mothers have an increased risk of hospital admission in the neonatal period for hypoglycemia, jaundice, respiratory distress, and asphyxia, and a greater need of intensive care. Obstetric trauma rates were similar in both groups (AU)